NEW YORK (GenomeWeb News) – Bioinformatics firm Genome Compiler has raised $500,000 toward a targeted round of $5 million, the company said in a document filed with the US Securities and Exchange Commission this week.

The Northern California-based firm did not identify investors in the round or say how the proceeds will be used. In its Form D filed with the SEC, it said that the type of securities offered comprised equity and security to be acquired upon exercise of option, warrant, or other right to acquire security.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.